Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease
Adrian G. Todd PhD
Department of Pediatrics, University of Florida, Gainesville, FL
Search for more papers by this authorJessica A. McElroy BSc
Department of Pediatrics, University of Florida, Gainesville, FL
Search for more papers by this authorRobert W. Grange PhD
Department of Human Nutrition, Foods and Exercise, Virginia Tech University, Blacksburg, VA
Search for more papers by this authorDavid D. Fuller PhD
Department of Physical Therapy, University of Florida, Gainesville, FL
Search for more papers by this authorGlenn A. Walter PhD
Department of Physiology and Functional Genomics, University of Florida, Gainesville, FL
Search for more papers by this authorCorresponding Author
Barry J. Byrne MD, PhD
Department of Pediatrics, University of Florida, Gainesville, FL
Address correspondence to Dr Darin J. Falk, 1200 Newell Drive, ARB/RG-148, P.O. Box 100296, Gainesville, FL 32610. E-mail: [email protected] and Dr Barry J. Byrne, 1200 Newell Drive, ARB/RG-183, P.O. Box 100296, Gainesville, FL 32610. E-mail: [email protected]Search for more papers by this authorCorresponding Author
Darin J. Falk PhD
Department of Pediatrics, University of Florida, Gainesville, FL
Address correspondence to Dr Darin J. Falk, 1200 Newell Drive, ARB/RG-148, P.O. Box 100296, Gainesville, FL 32610. E-mail: [email protected] and Dr Barry J. Byrne, 1200 Newell Drive, ARB/RG-183, P.O. Box 100296, Gainesville, FL 32610. E-mail: [email protected]Search for more papers by this authorAdrian G. Todd PhD
Department of Pediatrics, University of Florida, Gainesville, FL
Search for more papers by this authorJessica A. McElroy BSc
Department of Pediatrics, University of Florida, Gainesville, FL
Search for more papers by this authorRobert W. Grange PhD
Department of Human Nutrition, Foods and Exercise, Virginia Tech University, Blacksburg, VA
Search for more papers by this authorDavid D. Fuller PhD
Department of Physical Therapy, University of Florida, Gainesville, FL
Search for more papers by this authorGlenn A. Walter PhD
Department of Physiology and Functional Genomics, University of Florida, Gainesville, FL
Search for more papers by this authorCorresponding Author
Barry J. Byrne MD, PhD
Department of Pediatrics, University of Florida, Gainesville, FL
Address correspondence to Dr Darin J. Falk, 1200 Newell Drive, ARB/RG-148, P.O. Box 100296, Gainesville, FL 32610. E-mail: [email protected] and Dr Barry J. Byrne, 1200 Newell Drive, ARB/RG-183, P.O. Box 100296, Gainesville, FL 32610. E-mail: [email protected]Search for more papers by this authorCorresponding Author
Darin J. Falk PhD
Department of Pediatrics, University of Florida, Gainesville, FL
Address correspondence to Dr Darin J. Falk, 1200 Newell Drive, ARB/RG-148, P.O. Box 100296, Gainesville, FL 32610. E-mail: [email protected] and Dr Barry J. Byrne, 1200 Newell Drive, ARB/RG-183, P.O. Box 100296, Gainesville, FL 32610. E-mail: [email protected]Search for more papers by this authorAbstract
Objective
We have recently reported on the pathology of the neuromuscular junction (NMJ) in Pompe disease, reflecting disruption of neuronal and muscle homeostasis as a result of glycogen accumulation. The aim of this study was to examine how the alteration of NMJ physiology contributes to Pompe disease pathology; we performed molecular, physiological, and histochemical analyses of NMJ-related measures of the tibialis anterior muscles of young-, mid-, and late-stage alpha-glucosidase (GAA)-deficient mice.
Methods
We performed intramuscular injection of an adeno-associated virus (AAV)9 vector expressing GAA (AAV9-hGAA) into the tibialis anterior muscle of Gaa–/– mice at early, mid, and severe pathological time points. We analyzed expression of NMJ-related genes, in situ muscle force production, and clearance of glycogen in conjunction with histological assessment of the NMJ.
Results
Our data demonstrate that AAV9-hGAA is able to replace GAA to the affected tissue and modify AChR mRNA expression, muscle force production, motor endplate area, and innervation status. Importantly, the degree of restoration for these outcomes is limited by severity of disease. Early restoration of GAA activity was most effective, whereas late correction of GAA expression was not effective in modifying parameters reflecting NMJ structure and function nor in force restoration despite resolution of glycogen storage in muscle.
Interpretation
Our data provide new mechanistic insight into the pathology of Pompe disease and suggest that early systemic correction to both neural and muscle tissues may be essential for successful correction of neuromuscular function in Pompe disease. Ann Neurol 2015;78:222–234
Supporting Information
Additional Supporting Information may be found in the online version of this article.
| Filename | Description |
|---|---|
| ana24433-sup-0001-supptables.xlsx53.9 KB | Supplementary Information Tables |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010; 28: 271–274.
- 2Raben N, Plotz P, Byrne BJ. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2002; 2: 145–166.
- 3van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet 2008; 372: 1342–1353.
- 4Falk DJ, Mah CS, Soustek MS, et al. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. Mol Ther 2013; 21: 1661–1667.
- 5Mah C, Pacak CA, Cresawn KO, et al. Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol Ther 2007; 15: 501–507.
- 6Mah CS, Falk DJ, Germain SA, et al. Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther 2010; 18: 502–510.
- 7Raben N, Nagaraju K, Lee E, et al. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 1998; 273: 19086–19092.
- 8DeRuisseau LR, Fuller DD, Qiu K, et al. Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci U S A 2009; 106: 9419–9424.
- 9Elmallah MK, Falk DJ, Nayak S, et al. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in Pompe Mice. Mol Ther 2014; 22: 702–712.
- 10Falk DJ, Todd AG, Lee S, et al. Peripheral nerve and neuromuscular junction pathology in Pompe disease. Hum Mol Genet 2015; 24: 625–636.
- 11Bockstael O, Foust KD, Kaspar B, Tenenbaum L. Recombinant AAV delivery to the central nervous system. Methods Mol Biol 2011; 807: 159–177.
- 12Byrne BJ, Falk DJ, Pacak CA, et al. Pompe disease gene therapy. Hum Mol Genet 2011; 20: R61–R68.
- 13Dellorusso C, Crawford RW, Chamberlain JS, Brooks SV. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J Muscle Res Cell Motil 2001; 22: 467–475.
- 14Huguet A, Medja F, Nicole A, et al. Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus. PLoS Genet 2012; 8: e1003043.
- 15Metzger F, Sajid W, Saenger S, et al. Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I). J Biol Chem 2011; 286: 19501–19510.
- 16Schertzer JD, Ryall JG, Lynch GS. Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice. Am J Physiol Endocrinol Metab 2006; 291: E499–E505.
- 17de Chaumont F, Dallongeville S, Chenouard N, et al. Icy: an open bioimage informatics platform for extended reproducible research. Nat Methods 2012; 9: 690–696.
- 18Dowling JJ, Joubert R, Low SE, et al. Myotubular myopathy and the neuromuscular junction: a novel therapeutic approach from mouse models. Dis Model Mech 2012; 5: 852–859.
- 19Kong L, Wang X, Choe DW, et al. Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J Neurosci 2009; 29: 842–851.
- 20Joubert R, Vignaud A, Le M, et al. Site-specific Mtm1 mutagenesis by an AAV-Cre vector reveals that myotubularin is essential in adult muscle. Hum Mol Genet 2013; 22: 1856–1866.
- 21Corti M, Smith BK, Falk DJ, et al. Altered activation of the tibialis anterior in individuals with pompe disease: implications for motor unit dysfunction. Muscle Nerve 2014 Sep 3. doi: 10.1002/mus.24444. [Epub ahead of print]
10.1002/mus.24444 Google Scholar
- 22Conlon TJ, Erger K, Porvasnik S, et al. Preclinical toxicology and biodistribution studies of recombinant adeno-associated virus 1 human acid alpha-glucosidase. Hum Gene Ther Clin Dev 2013; 24: 127–133.
- 23Ziegler RJ, Bercury SD, Fidler J, et al. Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice. Hum Gene Ther 2008; 19: 609–621.
- 24Corti M, Elder M, Falk D, et al. B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol Ther Methods Clin Dev 2014; 1. pii: 14033.
10.1038/mtm.2014.33 Google Scholar
- 25Pratt SJ, Shah SB, Ward CW, et al. Recovery of altered neuromuscular junction morphology and muscle function in mdx mice after injury. Cell Mol Life Sci 2015; 72: 153–164.
- 26Harris JB, Ribchester RR. The relationship between end-plate size and transmitter release in normal and dystrophic muscles of the mouse. J Physiol 1979; 296: 245–265.
- 27Muller-Felber W, Horvath R, Gempel K, et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 2007; 17: 698–706.
- 28 American Association of Neuromuscular & Electrodiagnostic Medicine. Diagnostic criteria for late-onset (childhood and adult) Pompe disease. Muscle Nerve 2009; 40: 149–160.
- 29Burrow TA, Bailey LA, Kinnett DG, Hopkin RJ. Acute progression of neuromuscular findings in infantile Pompe disease. Pediatr Neurol 2010; 42: 455–458.
- 30Pongratz D, Kotzner H, Hubner G, Deufel T, Wieland OH. [Adult form of acid maltase deficiency presenting as progressive spinal muscular atrophy]. [Article in German]. Dtsch Med Wochenschr 1984; 109: 537–541.
- 31Gambetti P, DiMauro S, Baker L. Nervous system in Pompe's disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol 1971; 30: 412–430.
- 32Chien YH, Hwu WL, Lee NC. Pompe disease: early diagnosis and early treatment make a difference. Pediatr Neonatol 2013; 54: 219–227.
- 33Qiu K, Falk DJ, Reier PJ, et al. Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice. Mol Ther 2012; 20: 21–27.
- 34Parenti G, Fecarotta S, la Marca G, et al. A chaperone enhances blood alpha-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. Mol Ther 2014; 22: 2004–2012.
- 35Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 2006; 149: 89–97.
- 36Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004; 113: e448–e457.
- 37Klinge L, Straub V, Neudorf U, Voit T. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. Neuropediatrics 2005; 36: 6–11.
- 38Elmallah MK, Falk DJ, Nayak S, et al. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Mol Ther 2014; 22: 702–712.
- 39Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27: 59–65.
- 40Ahad MA, Narayanaswami P, Kasselman LJ, Rutkove SB. The effect of subacute denervation on the electrical anisotropy of skeletal muscle: implications for clinical diagnostic testing. Clin Neurophysiol 2010; 121: 882–886.
- 41Rakhilin S, Turner G, Katz M, et al. Electrical impedance as a novel biomarker of myotube atrophy and hypertrophy. J Biomol Screen 2011; 16: 565–574.
- 42Horvath JJ, Austin SL, Case LE, et al. Correlation between quantitative whole-body muscle MRI and clinical muscle weakness in Pompe disease. Muscle Nerve 2015; 51: 722–730.
- 43Kassardjian CD, Engel AG, Sorenson EJ. Electromyographic findings in 37 patients with adult-onset acid maltase deficiency. Muscle Nerve 2015; 51: 759–761.
- 44Zaidman CM, Wang LL, Connolly AM, et al. Electrical impedance myography in duchenne muscular dystrophy and healthy controls: a multi-center study of reliability and validity. Muscle Nerve 2015 Feb 20. doi: 10.1002/mus.24611. [Epub ahead of print]
10.1002/mus.24611 Google Scholar
- 45Li J, Geisbush TR, Rosen GD, et al. Electrical impedance myography for the in vivo and ex vivo assessment of muscular dystrophy (mdx) mouse muscle. Muscle Nerve 2014; 49: 829–835.
- 46Li J, Geisbush TR, Arnold WD, et al. A comparison of three electrophysiological methods for the assessment of disease status in a mild spinal muscular atrophy mouse model. PLoS One 2014; 9: e111428.
- 47Takikita S, Schreiner C, Baum R, et al. Fiber type conversion by PGC-1alpha activates lysosomal and autophagosomal biogenesis in both unaffected and Pompe skeletal muscle. PLoS One 2010; 5: e15239.
- 48Nascimbeni AC, Fanin M, Masiero E, et al. Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients. Autophagy 2012; 8: 1697–1700.
- 49Smith BK, Collins SW, Conlon TJ, et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther 2013; 24: 630–640.
Citing Literature
